Pancreatic Cancer Research

ResearcherUniversity of KansasActive in the last 2 years

Anup Kasi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-4305-5701; OpenAlex author ID A5006538210. Sources: ClinicalTrials.gov.

Their work

Papers
26 (first author 4, last author 5)
Trials
4 (principal investigator on 4)
Grants
0
Labs led
1
Collaborators
119
Papers, trials and grants by year

2018: 1 paper · 2019: 1 trial · 2020: 5 papers · 2021: 3 papers, 1 trial · 2022: 1 paper, 1 trial · 2023: 3 papers · 2024: 5 papers · 2025: 5 papers, 1 trial · 2026: 3 papers

Papers 26

  1. Setidegrasib in Advanced Non-Small-Cell Lung Cancer and Pancreatic Cancer. First author DOI 10.1056/nejmoa2600752↗
  2. Niraparib in pancreatic cancer with germline or somatic DNA damage repair (DDR) gene alterations (BRCA and beyond): a phase II study (NIRA-PANC). Co-author DOI 10.1093/oncolo/oyag225↗
  3. Metastatic Pancreatic Adenocarcinoma with Germline BLM and Somatic ATM Mutations: A Case Report and Review of DNA Damage Response. Last author DOI 10.29011/2574-7754.102521↗
  4. Pembrolizumab ± paricalcitol in metastatic pancreatic cancer postmaximal cytoreduction. Co-author DOI 10.1093/oncolo/oyae323↗
  5. Distinct Molecular and Clinical Features of Specific Variants of KRAS Codon 12 in Pancreatic Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-24-3149↗
  6. Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 St… Co-author DOI 10.1200/jco-25-00746↗
  7. Exceptional responders to immunotherapy in pancreatic cancer: A multi-institutional case series of a rare occurrence. Co-author DOI 10.18632/oncotarget.28739↗
  8. Prognostic significance of serum MUC5AC in resected pancreatic ductal adenocarcinoma: initial insights. Co-author DOI 10.3389/fonc.2025.1544928↗
  9. Comparative molecular profiling of pancreatic ductal adenocarcinoma of the head versus body and tail. Co-author DOI 10.1038/s41698-024-00571-4↗
  10. Association of personalized and tumor-informed ctDNA with patient survival outcomes in pancreatic adenocarcinoma. Co-author DOI 10.1093/oncolo/oyae155↗
  11. Protease activity-based nanobiosensors for early detection of pancreatic cancer. Co-author DOI 10.18103/mra.v12i7.5632↗
  12. Serum MUC5AC Predicts Recurrence in Pancreatic Ductal Adenocarcinoma Patients on Neoadjuvant Chemotherapy Co-author DOI 10.20944/preprints202409.0945.v1↗
  13. Mature MUC5AC Expression in Resected Pancreatic Ductal Adenocarcinoma Predicts Treatment Response and Outcomes. Co-author DOI 10.3390/ijms25169041↗
  14. Circulating Tumor Cell Subpopulations Predict Treatment Outcome in Pancreatic Ductal Adenocarcinoma (PDAC) Patients. First author DOI 10.3390/cells12182266↗
  15. Anticancer Activity of Novel Difluorinated Curcumin Analog and Its Inclusion Complex with 2-Hydroxypropyl-β-Cyclodextrin against Pancreatic Cancer. Co-author DOI 10.3390/ijms24076336↗
  16. Predictive Value of MUC5AC Signature in Pancreatic Ductal Adenocarcinoma: A Hypothesis Based on Preclinical Evidence. First author DOI 10.3390/ijms24098087↗
  17. A New Hope for Liquid Biopsies: Early Detection of Pancreatic Cancer By Means of Protease Activity Detection in Serum Applying a Hierarchical Decision Structure Co-author DOI 10.1101/2022.10.18.22281240↗
  18. Association of losartan with outcomes in metastatic pancreatic cancer patients treated with chemotherapy. Co-author DOI 10.18053/jctres.07.202102.008↗
  19. CHEK2 mutation in a patient with pancreatic adenocarcinoma-a rare case report. Last author DOI 10.21037/acr-20-83↗
  20. Efficacy and tolerability of the combination of nano-liposomal irinotecan and 5-fluorouracil/leucovorin in advanced pancreatic adenocarcinoma: post-approval cl… Co-author DOI 10.21037/jgo-20-338↗
  21. Diphenylbutylpiperidine Antipsychotic Drugs Inhibit Prolactin Receptor Signaling to Reduce Growth of Pancreatic Ductal Adenocarcinoma in Mice. Co-author DOI 10.1053/j.gastro.2019.11.279↗
  22. Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcin… Co-author DOI 10.1200/jco.20.00590↗
  23. Survival Outcomes of Pancreatic Intraepithelial Neoplasm (PanIN) versus Intraductal Papillary Mucinous Neoplasm (IPMN) Associated Pancreatic Adenocarcinoma. Last author DOI 10.3390/jcm9103102↗
  24. Association of Neutrophil, Platelet, and Lymphocyte Ratios with the Prognosis in Unresectable and Metastatic Pancreatic Cancer. Last author DOI 10.3390/jcm9103283↗
  25. Second-line treatment for metastatic pancreatic cancer. First author PMID 32558804↗
  26. Pathological complete response in pancreatic adenocarcinoma with FOLFIRINOX. Last author DOI 10.1136/bcr-2018-225621↗

Trials 4

  1. Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer Principal investigator NCT06736717↗
  2. Tg01 Vaccine / Qs-21 Stimulon™ With Or Without Balstilimab As Maintenance Therapy Following Adjuvant Chemotherapy In Patients With Resected Pancreatic Cancer Principal investigator NCT05638698↗
  3. CEND-1 in Combination with Neoadjuvant FOLFIRINOX with or Without Panitumumab Principal investigator NCT05121038↗
  4. Niraparib in Metastatic Pancreatic Cancer After Previous Chemotherapy (NIRA-PANC): a Phase 2 Trial Principal investigator NCT03553004↗

Closest collaborators

The 25 strongest of 119 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ravi Kumar Paluri · 8 shared papers, 2020–2026 · strength 1.53
  2. Ashish Manne · 5 shared papers, 2023–2026 · strength 1.09
  3. Prasad R. Dandawate · 5 shared papers, 2020–2026 · strength 0.81
  4. Ashwini Kumar Esnakula · 4 shared papers, 2023–2025 · strength 0.78
  5. Weijing Sun · 5 shared papers, 2020–2026 · strength 0.71
  6. Stefan H. Bossmann · 4 shared papers, 2021–2024 · strength 0.68
  7. Obdulia Covarrubias‐Zambrano · 3 shared papers, 2022–2024 · strength 0.54
  8. Upender Manne · 3 shared papers, 2024–2025 · strength 0.51
  9. Kannan Thanikachalam · 3 shared papers, 2024–2025 · strength 0.51
  10. Wancai Yang · 3 shared papers, 2024–2025 · strength 0.51
  11. Lianbo Yu · 3 shared papers, 2024–2025 · strength 0.51
  12. Ankur Sheel · 3 shared papers, 2024–2025 · strength 0.51
  13. Jordan M. Cloyd · 3 shared papers, 2024–2025 · strength 0.51
  14. Abdullah Esmail · 2 shared papers, 2024 · strength 0.39
  15. Maen Abdelrahim · 2 shared papers, 2024 · strength 0.39
  16. Steven A. Soper · 2 shared papers, 2023–2026 · strength 0.38
  17. Shrikant Anant · 3 shared papers, 2020–2023 · strength 0.38
  18. Deepak Sherpally · 2 shared papers, 2024–2025 · strength 0.36
  19. Anwaar Saeed · 2 shared papers, 2020–2026 · strength 0.34
  20. Bhargavram Channagiri Srinivas · 1 shared paper, 2026 · strength 0.32
  21. Sameek Roychowdhury · 2 shared papers, 2024 · strength 0.31
  22. Mary E. Dillhoff · 2 shared papers, 2024 · strength 0.31
  23. Anne M. Noonan · 2 shared papers, 2024 · strength 0.31
  24. Aslam M. Ejaz · 2 shared papers, 2024 · strength 0.31
  25. Shafia Rahman · 2 shared papers, 2024 · strength 0.31

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.